Janssen to Highlight Innovation in Retinal Pipeline at the Association for Research in Vision and Ophthalmology (ARVO) 2023 Annual Meeting | Johnson & Johnson
EU reviews J&J COVID-19 shot for rare nerve disorder after U.S. warning | Reuters
EU regulator meets to evaluate J&J's one-shot COVID-19 shot
Concerns over rare clotting disorders halt use of Johnson & Johnson's COVID-19 vaccine | Science | AAAS
Johnson & Johnson vaccine to be reviewed by EMA over possible blood clot links
EMA awards coveted PRIME designation for Janssen's CAR-T therapy
European Medicines Agency Recommends Johnson & Johnson Vaccine to EU
EU approves Johnson & Johnson COVID vaccine
Johnson & Johnson could apply for EMA approval in February | New Europe
Ema Johnson Interview - Nantucket Land Council
News - COVID-19 Vaccine Janssen – Possible Relation to very rare Cases of unusual Blood Clots in Combination with a reduced Platelet Count - Paul-Ehrlich-Institut
Janssen submits marketing authorisation to EMA for teclistamab - PMLiVE
EMA finds possible Johnson and Johnson blood clot link but 'benefits outweigh risks'
Johnson & Johnson Announces Submission of European Conditional Marketing Authorisation Application to the EMA for its Investigational Single-Shot Janssen COVID-19 Vaccine Candidate | Johnson & Johnson
EMA flags Johnson & Johnson COVID vaccine for rare disorder, passes mRNA shots for one side effect but probes another | Fierce Pharma
Johnson & Johnson's COVID-19 vaccine under scrutiny at EMA after 4 'serious cases' of unusual blood clots | Fierce Pharma
